Introduction
Breast cancer is the most commonly diagnosed neoplasm in women in the UK, causing over 45,000 new cases and 12,000 deaths annually (Office for National Statistics, 2009 ). In the 75% of invasive breast cancers that express the estrogen receptor (ER), estrogens are key promoters of tumorigenesis (Yager & Davidson, 2006) . It is surprising, therefore, that more than two-thirds of breast cancers occur in postmenopausal women when the ovaries cease to produce estrogen (Pasqualini, 2004) . However, despite the 90% reduction in plasma estradiol (E2) levels that occur with the menopause, the tissue concentrations of estrogens in normal breast tissue of pre-and post-menopausal women are comparable (Geisler, 2003; van Landeghem et al, 1985; Thijssen et al, 1986) . This reflects extragonadal biosynthesis of estrogens, which occurs in a number of peripheral tissues, including not only breast, but also adipose tissue, muscle, skin and bone (Suzuki et al, 2005) . These represent the main sites of estrogen synthesis beyond the menopause (Simpson et al, 1999) , which is derived from the conversion of circulating precursor C19 steroids. These include the androgens, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEAS) and androstenedione (Adione), which are primarily of adrenal origin (Couzinet et al, 2001 ).
The importance of local breast tissue estradiol production in the pathogenesis of breast carcinoma is supported by numerous studies which have reported tumor tissue estrogen levels being 2-20 fold elevated when compared to corresponding plasma levels (van Landeghem et al, 1985; Vermeulen et al, 1986; Pasqualini et al, 1996) . In fact, it has been demonstrated that in postmenopausal women, intratumoral estradiol levels are 2-3 fold higher than in areas considered as morphologically normal Page 4 of 26 A c c e p t e d M a n u s c r i p t (Bonney et al, 1983; Chetrite et al, 2000) . This suggests an augmented local tumoral biosynthesis and accumulation of these hormones which is thought to play an important role in the development of hormone-dependent breast cancer. Using in vitro approaches, a number of authors have confirmed the ability of human breast and its neoplasms to locally synthesize estrogens (Perel et al, 1980; Miller et al, 1982; Adams & Li, 1975; Varela & Dao, 1978) and in fact, Yue and co-workers demonstrated that in situ estradiol synthesis predominates over uptake from plasma in the maintenance of elevated intratumoral hormone concentrations (Yue et al, 1998a (Yue et al, , 1998b . Although there is overwhelming evidence for intracrine mechanisms of estrogen synthesis and action, the issue of quantitative contribution of local synthesis of estrogenic steroids versus uptake from circulation, remains controversial (Haynes et al, 2010) . These authors found a significantly higher concentration of E2 in tumors versus normal tissue which correlated significantly with ER+ status. Other alternative factors which can influence intra-tumoral E2 disposition, such as EST, STS and 17β-HSD1/7, cannot be excluded. However, the improvement in the sensitivity of the assay procedures may explain the discrepancy between the findings of Lønning et al.(2009) and those reported by Thijssen et al. (1987) . Clearly, components of both uptake and local synthesis are physiologically important (Yue et al. 1998a) . A c c e p t e d M a n u s c r i p t (Adione) is converted to estrone (E1) by aromatase (Miller et al, 1982) . The latter pathway utilizes inactive sulfated steroids, including estrone sulfate (E1S), as precursors. E1S is the predominant estrogen found in the circulation of postmenopausal women (Santner et al, 1984) . Although biologically inactive, its long half-life (Ruder et al, 1972) and high serum concentrations (Noel et al, 1981; Pasqualini, 2004 ) is thought to create a large reservoir which is utilized by steroid sulfatase (STS) for the formation of E1 by desulfonation. Of note, E1S, carrying a net negative charge, is hydrophilic and unable to cross cell membranes. It is thought that its uptake into cells involves specific transporter proteins, and the organic anion transport polypeptide B (OATP-B), has received particular attention in this respect. OATP-B (OATP2B1, SLCO2B1) has been reported to be expressed in both normal and neoplastic breast tissue (Al Sarakbi et al, 2006; Alcorn et al, 2002; Pizzagalli et al, 2003; Wlcek et al, 2008) . Additionally, immunoreactivity of human liver-specific transporter LST-2 (OATP8, SLCO1B3) was reported to be a potent prognostic factor in human breast cancer (Muto et al., 2007) . Therefore, breast tumors express the necessary machinery for the uptake and conversion of sulfated steroids into biologically active estrogens. Estrone sulfotransferase (EST), a member of the superfamily of steroid sulfotransferases, is also expressed in breast tissue and opposes the action of STS by sulfating El to ElS ). El, formed either through the aromatase or sulfatase pathways, is subsequently reduced to the biologically potent estradiol (E2), by 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). Oxidation (inactivation) of E2 to E1 is carried out by 17βHSD type 2 (17βHSD2) (Figure 1 ).
Expression of enzymes involved in synthesis of estrogenic steroids
The relevance and interplay between aromatase, STS, OATP-B and 17βHSDl to facilitate local synthesis of estrogenic steroids within breast and other tissues, is M a n u s c r i p t detailed in several excellent reviews (Nussbaumer & Billich, 2005; Ghosh, 2007; Buono & Cosma, 2010; Lin et al, 2010; Bojarova & Williams, 2008; Suzuki et al, 2009 ).
Studies examining the expression, immunoreactivity and/or activity of the above proteins have revealed their importance in breast carcinoma. For example, intratumoral aromatase and STS mRNA levels have been shown to be significantly elevated when compared to adjacent non-malignant tissues (Utsumi et al, 1996; Miki et al, 2007; Utsumi et al, 2000; Honma et al, 2006) . Indeed, STS activity has been reported to be 10-200 fold higher than that of aromatase in both pre-and postmenopausal breast cancer patients (Pasqualini et al, 1996; Chetrite et al, 2000; Santner et al, 1984) .
Additionally, STS immunoreactivity is detected more frequently in breast carcinomas (59-88% Suzuki et al, 2003; Tsunoda et al, 2006; Saeki et al, 1999) and compares well with that reported by others: 40-66.7% (Yamamoto et al 2003; Esteban et al, 1992; Santen et al, 1994; Lu et al, 1996; Shenton et al, 1998; Brodie et al, 2001 ) and it has been estimated that this pathway may be responsible for 10-fold greater intratumoral estradiol production (Santen et al, 1986) . STS has also been associated with a number of clinicopathological parameters in breast cancer patients such as tumor size, risk of recurrence, poor prognosis, reduced disease free survival and disease progression, whereas the data for aromatase is less conclusive (Silva et al, 1989; Lipton et al, 1992; Miyoshi et al, 2003; Suzuki et al, 2003 , Utsumi et al, 1999 Yoshimura et al, 2004) The literature also suggests a trend towards elevated OATP-B expression in malignant breast tissue, and higher mRNA levels of this transporter have been linked with increasing tumor grade (Al Sarakbi et al, 2006) . Although not necessarily over-
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A c c e p t e d M a n u s c r i p t expressed in breast cancer, several immunohistochemical studies have reported 17β-HSDl expression in approximately 50 to 60% of breast neoplasms (Poutanen et al, 1992; Sasano et al, 1996; Suzuki et al, 2000) . Additionally, 17β-HSDl gene amplification and expression have been associated with poor prognosis (Gunnarsson et al, 2008; Oduwole et al, 2004) . By contrast, 17β-HSD2 mRNA or immunoreactivity is frequently not detected in breast carcinomas (Suzuki et al, 2000; Gunnarsson et al, 2001) , and low expression, in conjunction with a high levels of 17β-HSD1, has prognostic significance and is associated with higher rates of recurrence in ER positive patients (Gunnarsson et al, 2001; Gunnarsson et al, 2005) . From these studies it is clear that 17β-HSD2, by inactivating E2, protects against tumor progression in normal breast tissue.
In recent years, the expression of other isoforms of 17β-HSD such as 17β-HSD7 and 17β-HSD12 has been described in breast cancer tissue and cell lines (Haynes et al, 2010; Day et al, 2009; Shehu et al, 2011) . The relative contribution of each of these isoforms to intra-tumoral E2 synthesis remains to be determined. The enzyme kinetic activities of each of these isoforms has not been independently determined. Selective knockdown with siRNA will further highlight the contribution of each isoform. In addition, in contrast to 17β-HSD1/2, the prognostic significance of these recent isoforms remains to be assessed. M a n u s c r i p t Therapeutic relevance of steroid sulfatase (a) Androstenediol: the underappreciated product of the steroid sulfatase pathway Apart from E1, the STS pathway is also responsible for the production of another steroid with estrogenic properties, namely androstenediol (Adiol). DHEAS, secreted exclusively by the adrenal cortex (Panjari & Davis, 2007) , is converted to DHEA by STS, which can subsequently be reduced to Adiol by 17β-HSD1. Adiol, although an androgen, can bind to the estrogen receptor, and has been shown to stimulate the proliferation of a number of ER-positive breast cancer cells in an ER-dependent manner (Poulin & Labrie, 1986; Aspinall et al, 2004) . Despite its lower affinity for the ER (Poulin & Labrie, 1986) , the 100-fold higher circulating concentrations of this hormone have led some to speculate that it may have equipotent estrogenic properties to E2 (Spinola et al, 1986) . In vivo rodent models of carcinogen induced mammary carcinomas have demonstrated the ability of Adiol to stimulate tumor growth, even in the presence of aromatase inhibitors, confirming that this hormone does not need to be further aromatized to reveal its estrogenic effects (Dauvois & Labrie, 1989 ). Billich and colleagues demonstrated for the first time that inhibition of STS blocked DHEASstimulated growth of MCF-7 breast cancer cells, an effect which was not reproduced by concurrent treatment with aromatase inhibitors (Billich et al, 2000) . This confirms that the STS pathway is responsible for the production of the estrogenic compound Adiol from DHEAS, and that this occurs in an aromatase-independent fashion. This is of At this junction, it is important to emphasise that the affinities of the substrates for the aromatase or STS are very different. For example, the Km of androstenedione for aromatase is 8-10 nM whereas that of E1S or DHEAS for STS is 7-14 µM. The progression (Calhoun et al, 2003; Morris et al, 2001) . It is tempting to speculate that this may be due to increased synthesis of Adiol, although this was not investigated A c c e p t e d M a n u s c r i p t directly in these studies. DHEAS levels have also been reported to increase equally with 12 months of adjuvant tamoxifen and letrozole treatment, again supporting the notion of a compensatory increase in the production of this adrenal androgen to overcome the endocrine blockade (Rossi et al, 2009 ).
Very recently, in elegant studies carried out by Chanplakorn et al (2010) , it has been reported that neoadjuvant treatment with exemestane caused a significant increment in . The important role of androgens in apocrine breast cancer is reviewed by .
In vitro, cancer cells exposed to a long-term E2-deprived environment, adapted by upregulation of signalling pathways involving ERα, HER-2/neu, EGFR and IGFR. These pathways signal through MAPK, PI3K and mTOR and the cross-talk between these M a n u s c r i p t pathways is believed to drive proliferation. These pathways have also been shown to be activated in in vivo models of development of resistance to aromatase inhibitors by the group of Angela Brodie. A combination of traztuzumab with letrozole is found to be superior to the aromatase inhibitor alone in these xenograft models (reviewed in: Santen et al. 2009 ).
Lessons learnt from clinical trials with enzyme inhibitors
Many clinical trials have now been carried out with the third-generation aromatase inhibitors but so far only one phase I trial with a STS inhibitor has been conducted (Smith & Dowsett, 2003; Coombes et al. 2004; Stanway et al. 2006) . Measurement of serum oestrogen concentrations by RIA, employed as a surrogate marker of the effectiveness of AIs, is not straight forward and in some early studies it was difficult to detect the real effects of aromatase inhibitors from such measurements. More recently, very sensitive RIAs have been developed involving solvent extraction and chromatographic separation of oestrogens prior to RIA (Lonning & Ekse, 1995; Lonning et al, 1997) . However, a 'gold standard' GC-MS/MS method has now been developed for the measurement of serum oestrogens (Sundaram et al, 2003) . Using highly sensitive RIAs, there is no doubt that in most cases, plasma or serum levels of E1 and E2 are suppressed to below the limits of quantitation of the assays by thirdgeneration aromatase inhibitors (Geisler et al, 2002) . For E1S, while levels has been found to be suppressed by >98% by third-generation aromatase inhibitors, the geometric mean E1S concentrations after 16 weeks treatment with letrozole was 3.9pmol/l (Geisler et al, 2008) . As most patients treated with aromatase inhibitors will eventually progress, it is possible that the low levels of E1S still detectable may A c c e p t e d M a n u s c r i p t contribute to tumor cells becoming resistant to this form of therapy. Although these plasma levels of E1S are very low it is now well documented that breast cancer cells, grown in an estrogen-deprived environment, can become sensitive to extremely low estrogen concentrations (Masamura et al, 1995) .
In contrast to the problems associated with measuring aromatase activity in patients, the effects of STS inhibitors can be readily assessed. STS is present in peripheral blood lymphocytes (PBLs) and the extent and duration of STS inhibition can be readily determined by measuring its activity in these cells (Purohit et al, 1995) . In the first ever phase I trial of Irosustat (STX64, BN83495), STS activity, as measured in PBLs, was suppressed by >95% at the 5 mg/day and 20 mg/day doses tested (Stanway et al, 2006) . This level of STS inhibition was associated with moderate, but significant, reductions in the median concentrations of E1 (57-76%), E2 (38-39%) and testosterone (27-30%).
In addition, the median concentration of the steroid with oestrogenic properties, Adiol, decreased by 70-74%. Unexpectedly, serum Adione median concentrations also decreased by 62-72% indicating that, at least in postmenopausal women, a significant proportion of this steroid is derived from the peripheral conversion of DHEAS. The results from the STX64 phase I trial therefore show that while median serum concentrations of Adiol, Adione and E1 all decreased by approximately 70%, the reductions for testosterone and E2 were less, at about 30%.
Similar results were obtained in a second dose-escalation study of Irosustat in postmenopausal women with ER+ve metastatic breast cancer (Coombes et al, 2009 ).
Patients were recruited into 5 sequential dose cohorts (1, 5, 20, 40 and 80mg) . The optimum biological dose was determined to be 40mg. At this dose, Adiol concentrations decreased by 34-74% and E2 concentrations decreased by 7-27%. M a n u s c r i p t
Disease stabilization of 7-13 months was demonstrated in 3 of 14 patients who received >3 months treatment. Considering that the aromatase pathway of estrogen synthesis was not inhibited in these patients, the reduction in serum hormone concentrations and the disease stabilization obtained in some patients, were very encouraging. Currently, Phase II studies in women with endometrial cancer are in progress (www.ipsen.com).
Endometrial cancer is the most common gynecological malignancy with an unmet need for better therapy. When measured by validated mass spectrometry assays, circulating levels of E1, E2 and E1S were found to be significantly higher in women with Sasano and Harada ).
Although this review has focused on the potential use of STS inhibitors for the treatment of hormone-dependent cancers, they could also have therapeutic efficacy in a number of other conditions that still remain to be explored. STS is ubiquitously distributed throughout the body and may have important roles in regulating the production of androgens in a number of skin conditions (Reed et al, 2008) and part of the immune response (Rook et al. 1994; Reed et al. 2003) . In addition, little is known about the role of STS in normal male and female reproduction although there is A c c e p t e d M a n u s c r i p t evidence that STS inhibitors could be effective in conditions such as endometriosis (Purohit et al. 2008) . With the advent of potent STS inhibitors it will, for the first time, be possible to explore their therapeutic potential in a wide range of normal and abnormal conditions.
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